A clinical evaluation of long-term continuous use of norethynodrel-mestranol for contraception.
D000328:Adult; D000469:Alkaline Phosphatase / Q000097:blood; D001786:Blood Glucose / Q000032:analysis; D001835:Body Weight / Q000187:drug effects; D003276:Contraceptives, Oral / Q000009:adverse effects / Q000494:pharmacology*; D004716:Endometritis / Q000139:chemically induced; D005260:Female; D006400:Hematocrit; D006801:Humans; D006973:Hypertension / Q000139:chemically induced; D007889:Leiomyoma / Q000139:chemically induced; D007958:Leukocyte Count; D008656:Mestranol / Q000009:adverse effects / Q000494:pharmacology*; D008875:Middle Aged; D009641:Norethynodrel / Q000009:adverse effects / Q000494:pharmacology*; D010298:Parity; D011247:Pregnancy; D013997:Time Factors; D002579:Uterine Cervical Erosion / Q000139:chemically induced; D014594:Uterine Neoplasms / Q000139:chemically induced
D001786:Blood Glucose; D003276:Contraceptives, Oral; D009641:Norethynodrel; D008656:Mestranol; D000469:Alkaline Phosphatase